For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, General Manager,
Corporate Communications Department
Telephone: +81-3-6225-1126

Result of the Open Offer for Shares in Ranbaxy Laboratories Limited

Tokyo, October 17, 2008 — Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) announced today that the payment has been settled for the shares purchased on the open offer for common shares in Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359; Head Office in Delhi, India) (“Ranbaxy”) which was conducted during the period from August 16, 2008 to September 4, 2008 (the “Offer”). The details are summarized below.

Outline of the Offer
(1) Offer Period:
   From August 16, 2008 through September 4, 2008, the Indian Standard Time (20 days)
(2) Type of Share Certificates, etc. subject to the Offer:
   Common stock
(3) Offer Price:
   Rs737 per share

Result of the Offer
Number of Shares Planned to be Purchased: Maximum 92,519,126 shares (20%)
Number of Shares accepted: 92,519,126 shares (20%)

Note: Each percentage shown above represents the ratio to the total shares issued on a fully diluted basis, i.e., including all Foreign Currency Convertible Bonds, outstanding ESOPs, Preferential allotment of shares but excluding the Warrants described below.

Fund for the Purchase
Rs68,186 million (JPY170,466 million at Rs1=JPY2.5)

Note: The fund for the purchase is the amount obtained by multiplying the number of shares to be purchased (92,519,126 shares) by the offer price (Rs737 per share).

As required under Regulation 22(12) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto, Daiichi Sankyo has agreed to pay interest to the shareholders of Ranbaxy who had validly tendered their shares and which were accepted by Daiichi Sankyo, for delay in payment of consideration beyond 15 days from the closing of the offer period.
In accordance with the direction received from SEBI, Daiichi Sankyo has, along with the aforementioned amount paid interest to such shareholders of Ranbaxy.

Daiichi Sankyo had entered into a Share Purchase and Share Subscription Agreement on June 11, 2008 for a series of transactions pursuant to which Daiichi Sankyo would achieve holding 50.1% or more of the voting capital of Ranbaxy (the “Transaction”).

In addition to the Offer which has now been completed, Daiichi Sankyo is hereafter expected to acquire the equity stake in Ranbaxy by a combination of (i) purchase of shares held by the Singh family (“Sellers”), (ii) preferential allotment of equity shares, and (iii) subscription of warrants. The progress of procedure will be disclosed in due course.

(Reference: Transaction Summary)
- Acquisition by the Offer 92,519,126 shares (Maximum)
- Acquisition from the Sellers 129,934,134 shares
- Acquisition by Preferential Allotment of Shares 46,258,063 shares
- Subscription of Warrants Equivalent to 23,834,333 shares
  (At the time of subscription only 10% of the exercise price is payable)